After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, DMAC falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of DiaMedica Therapeutics Inc is $441.10M. A total of 89148.0 shares were traded on the day, compared to an average of 398.94K shares.
In the most recent transaction, STAHLBERG JAN bought 240,352 shares of DMAC for 7.21 per share on Nov 19 ’25. After the transaction, the 10% Owner now owns 8,375,092 company shares. In a previous transaction on Nov 21 ’25, STAHLBERG JAN bought 208,872 shares at 7.41 per share. DMAC shares that 10% Owner owns now total 8,712,390.
Among the insiders who bought shares, STAHLBERG JAN acquired of 182,882 shares on Nov 18 ’25 at a per-share price of $6.75. This resulted in the 10% Owner holding 8,134,740 shares of DMAC after the transaction. In another insider transaction, STAHLBERG JAN bought 187,393 shares at $6.52 per share on Nov 17 ’25. Company shares held by the 10% Owner now total 7,951,858.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, DMAC has a high of $10.42 and a low of $3.19.
As of this writing, DMAC has an earnings estimate of -$0.18 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.17 per share and a lower estimate of -$0.2. The company reported an EPS of -$0.18 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. DMAC’s latest balance sheet shows that the firm has $45.11M in Cash & Short Term Investments as of fiscal 2021. There were $52.00k in debt and $1.52M in liabilities at the time. Its Book Value Per Share was $0.99, while its Total Shareholder’s Equity was $44.02M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DMAC is Buy with a score of 4.67.
